Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen

Breast

Volumn 9, Issue 1, 2000, Pages 9-16

  Freue, M ^a   Kjaer, M ^j   Boni, C ^b   Joliver, J ^j   Janicke F ^j   Willemse, H B ^c   Coombes, R C ^d   Van Belle, S ^e   Perez Carrion R ^f   Zieschang, J ^g   Ibarra De Palacios, P ^h   Rose, C ⁱ  

^a Hosp Interzonal Agudos 'Evita' L   (Argentina)

^b Ospedale Civile   (Italy)

^c NOTRE DAME HOSPITAL   (Canada)

^d CHARING CROSS HOSPITAL   (United Kingdom)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g Novartis Germany   (Germany)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ ODENSE UNIVERSITY HOSPITAL   (Denmark)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; FORMESTANE; GESTAGEN; MEGESTROL ACETATE; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EDEMA; FEMALE; HOT FLUSH; HUMAN; HYPERTENSION; INJECTION PAIN; INJECTION SITE; MAJOR CLINICAL STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RASH; SWEATING; VAGINA BLEEDING; VERTIGO; WEIGHT GAIN;

EID: 0034065830     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.1999.0118     Document Type: Article

References (32)

1. Harmsen H J Jr, Porsius A J. Endocrine therapy of breast cancer. Eur J Cancer Clin Oncol. 24:1988;1099-1116.
2. Løber J, Mouridsen H T, Rose C. Oral or intramuscular treatment of advanced breast cancer with medroxyprogesterone acetate (MPA). A review. Role of MPA in endocrine-related tumours. 1983;Raven Press, New York. p. 105-114.
3. Wilson A J. Response in breast cancer to a second hormonal therapy. Rev Endocrine-Related Cancer. 14:1983;5-11.
4. Stoll B A. Combination endocrine therapy - concurrent or sequential. Stoll B A. Endocrine management of breast cancer. Part II, contemporary therapy. 1988;80-101 Karger, Basle.
5. Falkson C I, Falkson G, Falkson H C. Postmenopausal breast cancer. Drug therapy in the 1990's. Drugs and Aging. 3:1993;106-121.
6. Canny P A, Priestmann T J, Griffiths T. Randomised trial comparing aminoglutethimide with high dose medroxyprogesterone acetate for advanced breast carcinoma. J Natl Cancer Inst. 80:1988;1147-1151.
7. Lipton A, Harvery H A, Staten R J. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res. 42:1982;3434s.
8. Petru E, Schmähl D. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate, and aminoglutethimide in advanced breast cancer. Klin Wochenschr. 65:1987;959-966.
9. Smith J E, Harris A L, Morgan M. Tamoxifen versus aminoglutethimide in advanced breast carcinoma, a randomised cross-over trial. Br Med J. 283:1981;1432-1434.
10. Lundgrunden S, Gunersen S, Klepp R. Megestrol acetate vs. aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat. 14:1989;201-206.
11. Rose C, Mouridsen H T. Endocrine management of advanced breast cancer. Horm Res. 32:1989;189-196.
12. Garcia-Giralt E, Ayme Y, Carton M. Second- and third-line hormonotherapy in advanced postmenopausal breast cancer, a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat. 24:1992;139-145.
13. Allegra J C. Megestrol acetate, A new role in the treatment of metastatic breast cancer. Sem Hematol. 24:1987;45-47.
14. Ross M B, Buzdar A U, Blumenschein G R. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer. 49:1982;113-117.
15. Wander H E, Kleeberg U R, Gaertner E. Megestrolazetat in der Behandlung metastasierender Mammakarzinome. Onkologie. 10:1987;104-106.
16. Gregory E J, Cohen S C, Oines D W. Megestrol acetate therapy for advanced breast cancer. J Clin Oncol. 3:1985;15-18.
17. Robertson J F R, Williams M R, Todd J. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Clin Oncol. 25:1989;469-475.
18. Alexieva-Figusch J, van Gilse H A, Hop W C J. Progestin therapy in advanced breast cancer, megestrol acetate - an evaluation of 160 treated cases. Cancer. 46:1980;2369.
19. Ansfield F J, Kallas G J, Singson J P. Clinical results with megestrol acetate in patients with advanced carcinoma of the breast. Surg Gynecol Obstet. 155:1982;888.
20. Brodie A M H, Dowsett M, Coombes R C. Aromatase inhibitors and control of breast cancer. Proceedings of the Seventy-Eights Annual Meeting of the American Association for Cancer Research. 1987;AACR, Atlanta. p. 472-473.
21. Santen R J, Brodie A M H. Suppression of oestrogen production as treatment of breast carcinoma, Pharmacological studies with aromatase inhibitors. Furr B J A. Clinics in Oncology 1, No. 1. 182;77-130 Saunders, London.
22. Royce C. Formestane. Drugs of the Future. 1993;. p. 599-600.
23. Pérez Carrión R, Alberola Candel V, Calabresi F. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Am Oncol. 5:1994;19-24.
24. Monfardini S, Brunner K, Crowther D. UICC - Manual of Adult and Paediatric Medical Oncology. 1987;22-38.
25. Handbook for Reporting Results of Cancer Treatment. 1979;WHO Offset Publications, Geneva. p. 7.
26. Alexieva-Figusch J, Blankenstein M A, Hop W C J. Treatment of metastatic breast cancer patients with different dosages of megestrol acetate, dose relations, metabolic and endocrine effects. Eur J Cancer Clin Oncol. 20:1984;33-40.
27. Barnhart F R. PDR. Physician's Desk Reference. 1995;Medical Economics Company, Orandel.
28. Lachin J M, Foulkes M A. Evaluation of sample size and analysis of survival with allowance for nonuniform patient entry, losses to follow-up, non-compliance, and stratification. Biometrics. 42:1986;507-519.
29. Kjaer M. Combining 5-fluorouracil with interferon-a in the treatment of advanced colorectal cancer, optimism followed by disappointment. Anti-Cancer Drugs. 7:1996;35-42.
30. Buzdar A U, Jonat W, Howell A. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of date from two mature phase III trials. Arimedex Study Group. Cancer. 83:1998;1142-1152.
31. Dombernowsky P, Smith I, Falkson G. Letrozole, a new oral aromatase inhibitor for advanced breast cancer, Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 16:1998;453-461.
32. Gerschanovic M, Chaudri H A, Campos D. Lerozole, a new oral aromatase inhibitor, Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol. 9:1998;639-645.